Schonfeld Strategic Advisors LLC Sells 16,028 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Schonfeld Strategic Advisors LLC lowered its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 5.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 262,295 shares of the company's stock after selling 16,028 shares during the period. Schonfeld Strategic Advisors LLC owned approximately 0.38% of Akero Therapeutics worth $7,297,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in AKRO. Sterling Capital Management LLC boosted its holdings in Akero Therapeutics by 764.3% in the fourth quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after purchasing an additional 1,582 shares during the last quarter. Quarry LP purchased a new position in shares of Akero Therapeutics in the 4th quarter worth $83,000. Summit Investment Advisors Inc. increased its position in Akero Therapeutics by 6.8% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock valued at $197,000 after acquiring an additional 450 shares during the last quarter. Hsbc Holdings PLC lifted its holdings in Akero Therapeutics by 8.5% in the fourth quarter. Hsbc Holdings PLC now owns 7,886 shares of the company's stock valued at $220,000 after acquiring an additional 621 shares during the period. Finally, AlphaQuest LLC boosted its position in Akero Therapeutics by 32,588.0% in the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock worth $227,000 after purchasing an additional 8,147 shares during the last quarter.

Insider Transactions at Akero Therapeutics

In related news, COO Jonathan Young sold 607 shares of the business's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $27,242.16. Following the sale, the chief operating officer now owns 200,540 shares in the company, valued at approximately $9,000,235.20. The trade was a 0.30 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Cheng sold 30,000 shares of the stock in a transaction on Monday, February 10th. The shares were sold at an average price of $52.73, for a total transaction of $1,581,900.00. Following the transaction, the chief executive officer now owns 686,062 shares of the company's stock, valued at $36,176,049.26. This trade represents a 4.19 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 217,458 shares of company stock valued at $9,733,261 in the last ninety days. Corporate insiders own 7.94% of the company's stock.

Akero Therapeutics Price Performance

AKRO traded up $0.05 on Monday, hitting $44.92. 888,470 shares of the company's stock traded hands, compared to its average volume of 879,975. Akero Therapeutics, Inc. has a one year low of $17.86 and a one year high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The firm has a market cap of $3.58 billion, a price-to-earnings ratio of -11.98 and a beta of -0.12. The company's 50 day simple moving average is $41.66 and its 200-day simple moving average is $37.12.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings data on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing the consensus estimate of ($0.98) by ($0.01). As a group, research analysts anticipate that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Analyst Ratings Changes

AKRO has been the topic of several recent research reports. Citigroup increased their price objective on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Morgan Stanley reiterated an "overweight" rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Canaccord Genuity Group upped their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. UBS Group lifted their target price on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research report on Friday, January 31st. Finally, HC Wainwright upped their price target on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research report on Monday, March 3rd. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $76.29.

Akero Therapeutics Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.